Retatrutide Canada: Research Guide for Sourcing & Handling | Prescott Bio

Prescott Bio Editorial · ·
  • retatrutide
  • glp-1
  • metabolic
  • canada
  • research-guide

Key takeaways

  • Retatrutide is a synthetic triple-agonist peptide (GLP-1 / GIP / glucagon) supplied lyophilized for pre-clinical research.
  • A useful lot CoA carries HPLC purity ≥98% by area and a mass-spec identity match — not a template summary.
  • Domestic Canadian dispatch (2–4 business days from British Columbia) avoids CBSA cold-chain risk on cross-border peptide freight.

Retatrutide is a synthetic GLP-1 / GIP / glucagon triple agonist supplied for pre-clinical research. This guide covers three things Canadian research buyers ask before ordering: what the molecule is, what a good lot CoA looks like, and how cold-chain works for domestic Canadian dispatch.

What is Retatrutide, structurally?

Retatrutide is a synthetic peptide agonist reported in the published literature as active at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. The triple-agonist profile is what sets it apart from earlier GLP-1 mono-agonists like semaglutide and dual GLP-1 / GIP agonists like tirzepatide, both of which sit adjacent to it in the same research series. Its discovery lineage traces back to Eli Lilly’s incretin peptide research program, and the compound has since moved through phase-I and phase-II research in metabolic disease models.

Structurally, retatrutide is a modified peptide — a linear amino-acid backbone with lipid-modified residues that extend circulating half-life in animal models. That structural class is why it is supplied as a lyophilized powder rather than a small-molecule crystalline form, and why cold-chain handling matters more than it would for a stable small-molecule agonist. The peptide backbone is degradable, sensitive to repeated freeze-thaw cycles, and light-sensitive over long storage windows.

For laboratory work, the mechanism is what makes it interesting: a single molecule producing coordinated receptor engagement across three related pathways gives researchers a comparatively clean tool for studying combined incretin biology, without the confound of dosing three separate agonists in parallel.

What does the published pre-clinical and Phase-II data actually show?

Published phase-I and phase-II literature on retatrutide has appeared across peer-reviewed metabolic research journals over the last several years. At a high level, the reported work has covered pharmacokinetic profiling, receptor-binding characterization, and dose-ranging in metabolic and body-composition endpoints. The trials cited in the literature are conducted under regulated clinical protocols and are not a source of dosing guidance for laboratory research work.

For Canadian researchers building a bench protocol, the more useful sources are the pre-clinical publications that predate the human trials: receptor-affinity assays, in vitro potency comparisons against reference peptides in the same class, and animal-model pharmacology papers. Those describe the molecule’s behaviour in the systems most laboratory work actually replicates.

We deliberately do not summarize specific dosing schedules from human trials here. Retatrutide is supplied for laboratory research use only, and translating clinical dose ranges into research protocols is outside the scope of a supplier’s editorial content. Researchers designing experiments should work from the published pre-clinical literature and their own institutional protocol review.

What should a Canadian lab check before ordering Retatrutide?

The research-use-only (RUO) framework is the starting point for any sourcing conversation in Canada. Retatrutide supplied for RUO purposes is intended for in vitro and pre-clinical laboratory research; it is not sold, labelled, or represented as a therapeutic product. That framing shapes how the material is dispatched, labelled, and documented.

Domestic Canadian dispatch has become the practical default for most research buyers. Cross-border shipments — from US or overseas suppliers into Canada — routinely encounter Canada Border Services Agency inspection delays on peptide-classified freight, and cold-chain integrity degrades quickly when a shipment sits in a warehouse for two or three additional days waiting for release. A domestic Canadian ship-point removes the border variable entirely and typically means 2-4 business days door-to-door within Canada.

The other practical consideration is documentation. Each lot of retatrutide should ship with a lot-specific certificate of analysis from the assay lab, not a template CoA reused across lots. Researchers doing method-development work will want the actual chromatogram or a summary of peak areas — that context is what makes a CoA useful downstream.

For an overview of what a compliant Canadian Retatrutide supply looks like end-to-end, see the Retatrutide Canada reference lander.

How do I read a Retatrutide CoA — what should be on it?

A Retatrutide certificate of analysis should carry, at minimum, the following data points. Reading them in order gives you a fast sanity check on whether the lot is worth ordering.

For the full CoA reference standard we use for domestic Canadian dispatch, see the certificate of analysis reference.

How do I store Retatrutide, and does it need a cold chain?

Lyophilized retatrutide, sealed under vacuum in the original vial, is stable at 2-8 °C for the timeframes reported by the assay lab — typically at least twelve months for a fresh lot. For long-term storage beyond six months, laboratories generally move sealed vials to -20 °C freezer storage. Keep the vials in the original amber packaging or in an opaque container; peptide backbones with lipid modifications like retatrutide’s can be slowly degraded by prolonged light exposure.

Once reconstituted, the working stability window shortens considerably. Reconstituted retatrutide should be stored at 2-8 °C and used within a research-defined window — most published pre-clinical protocols use a 30-day working window at 2-8 °C, with longer-term aliquots frozen at -20 °C. Avoid repeated freeze-thaw cycles: each cycle can generate additional degradation product and shifts the impurity profile of the working stock.

For cold-chain during transit, domestic Canadian dispatch typically uses an insulated shipper with a phase-change coolant sized for a 48-72 hour window. Confirm the temperature indicator on receipt before signing off on the lot.

Retatrutide sits alongside two other reference topics we cover on this blog:

Where can I buy Retatrutide in Canada without cross-border risk?

Prescott Bio supplies retatrutide from a domestic Canadian ship-point with lot-tested vials and a lot-specific certificate of analysis. Three vial sizes are stocked as standard research SKUs: Retatrutide 10mg, Retatrutide 20mg, and Retatrutide 30mg. The 10mg format is the most common bench SKU; larger presentations are used by groups running larger animal-model cohorts or preparing extended aliquot sets.

Retatrutide typically pairs with other metabolic-intent research peptides in comparative work — see the metabolic research protocol reference for the standard pairing set, and the full Retatrutide Canada lander for the current lot’s CoA and ship-window status.

All retatrutide supplied through Prescott Bio is for laboratory research use only.